Core Insights - The company, YuanDa Pharmaceutical Group, has showcased significant clinical potential for its innovative nuclear medicine product, Yttrium-90 microsphere injection, at major oncology conferences [1][2] - The product is the only one globally approved for selective internal radiation therapy (SIRT) for colorectal cancer liver metastases and has been used by over 150,000 patients across more than 50 countries since its launch in May 2022 [1][2] Conference Highlights - The ASCO and APPLE conferences are recognized as authoritative platforms in the oncology field, with ASCO being the largest and most prestigious clinical oncology meeting globally [1] - At the ASCO conference, the Yttrium-90 microsphere injection was highlighted in two studies from leading Chinese research teams, indicating its prominence in hepatocellular carcinoma (HCC) treatment [2] Market Position and Financials - YuanDa Pharmaceutical is one of only four companies worldwide to have successfully commercialized nuclear medicine [2] - By the end of 2024, the Yttrium-90 microsphere injection is expected to have treated nearly 2,000 patients, generating approximately HKD 500 million in sales revenue [2] Future Development Plans - The company plans to enhance its nuclear medicine oncology treatment segment by expanding its product pipeline, which currently includes 15 innovative products across various radioactive isotopes targeting multiple cancer types [2] - The focus will be on establishing a product cluster centered around the Yttrium-90 microsphere injection to solidify its leadership position in the global nuclear medicine oncology market [2]
远大医药核药亮相ASCO及APPLE年会 持续夯实核药抗肿瘤诊疗业务